Logo image of PTPI

PETROS PHARMACEUTICALS INC (PTPI) Stock Fundamental Analysis

NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD

0.0664  -0.06 (-46.45%)

After market: 0.0356 -0.03 (-46.39%)

Fundamental Rating

1

Taking everything into account, PTPI scores 1 out of 10 in our fundamental rating. PTPI was compared to 195 industry peers in the Pharmaceuticals industry. PTPI may be in some trouble as it scores bad on both profitability and health. PTPI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PTPI has reported negative net income.
PTPI had a negative operating cash flow in the past year.
In the past 5 years PTPI always reported negative net income.
PTPI had a negative operating cash flow in each of the past 5 years.
PTPI Yearly Net Income VS EBIT VS OCF VS FCFPTPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -251.96%, PTPI is doing worse than 92.39% of the companies in the same industry.
Industry RankSector Rank
ROA -251.96%
ROE N/A
ROIC N/A
ROA(3y)-118.22%
ROA(5y)-79.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTPI Yearly ROA, ROE, ROICPTPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

With an excellent Gross Margin value of 76.28%, PTPI belongs to the best of the industry, outperforming 84.26% of the companies in the same industry.
PTPI's Gross Margin has improved in the last couple of years.
PTPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.38%
GM growth 5Y7.84%
PTPI Yearly Profit, Operating, Gross MarginsPTPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTPI has more shares outstanding
PTPI has more shares outstanding than it did 5 years ago.
PTPI has a worse debt/assets ratio than last year.
PTPI Yearly Shares OutstandingPTPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
PTPI Yearly Total Debt VS Total AssetsPTPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PTPI has an Altman-Z score of -18.76. This is a bad value and indicates that PTPI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PTPI (-18.76) is worse than 80.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.76
ROIC/WACCN/A
WACC6.75%
PTPI Yearly LT Debt VS Equity VS FCFPTPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.40 indicates that PTPI may have some problems paying its short term obligations.
PTPI has a worse Current ratio (0.40) than 93.91% of its industry peers.
A Quick Ratio of 0.33 indicates that PTPI may have some problems paying its short term obligations.
PTPI's Quick ratio of 0.33 is on the low side compared to the rest of the industry. PTPI is outperformed by 93.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.33
PTPI Yearly Current Assets VS Current LiabilitesPTPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.32% over the past year.
PTPI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -57.42%.
PTPI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.98% yearly.
EPS 1Y (TTM)14.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320.26%
Revenue 1Y (TTM)-57.42%
Revenue growth 3Y-13.17%
Revenue growth 5Y-19.98%
Sales Q2Q%-87.54%

3.2 Future

PTPI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.51% yearly.
PTPI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.00% yearly.
EPS Next Y48.83%
EPS Next 2Y21.8%
EPS Next 3Y18.67%
EPS Next 5Y18.51%
Revenue Next Year0.76%
Revenue Next 2Y0.17%
Revenue Next 3Y26.71%
Revenue Next 5Y43%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTPI Yearly Revenue VS EstimatesPTPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PTPI Yearly EPS VS EstimatesPTPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
Also next year PTPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTPI Price Earnings VS Forward Price EarningsPTPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTPI Per share dataPTPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

A more expensive valuation may be justified as PTPI's earnings are expected to grow with 18.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.8%
EPS Next 3Y18.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (5/21/2025, 8:00:01 PM)

After market: 0.0356 -0.03 (-46.39%)

0.0664

-0.06 (-46.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners1.13%
Inst Owner Change1046.18%
Ins Owners1.01%
Ins Owner Change95.98%
Market Cap2.07M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.63%
Min Revenue beat(2)-44.58%
Max Revenue beat(2)15.32%
Revenue beat(4)1
Avg Revenue beat(4)-8.97%
Min Revenue beat(4)-44.58%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-91.45
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.16
BVpS-0.24
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -251.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.28%
FCFM N/A
ROA(3y)-118.22%
ROA(5y)-79.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.38%
GM growth 5Y7.84%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.87%
Cap/Sales 0.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.33
Altman-Z -18.76
F-Score5
WACC6.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320.26%
EPS Next Y48.83%
EPS Next 2Y21.8%
EPS Next 3Y18.67%
EPS Next 5Y18.51%
Revenue 1Y (TTM)-57.42%
Revenue growth 3Y-13.17%
Revenue growth 5Y-19.98%
Sales Q2Q%-87.54%
Revenue Next Year0.76%
Revenue Next 2Y0.17%
Revenue Next 3Y26.71%
Revenue Next 5Y43%
EBIT growth 1Y53.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.87%
OCF growth 3YN/A
OCF growth 5YN/A